CN101732303A - 益母草碱用于更年期病症医药用途 - Google Patents
益母草碱用于更年期病症医药用途 Download PDFInfo
- Publication number
- CN101732303A CN101732303A CN200810181028A CN200810181028A CN101732303A CN 101732303 A CN101732303 A CN 101732303A CN 200810181028 A CN200810181028 A CN 200810181028A CN 200810181028 A CN200810181028 A CN 200810181028A CN 101732303 A CN101732303 A CN 101732303A
- Authority
- CN
- China
- Prior art keywords
- leonurine
- climacteric
- climacteric syndrome
- medicine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 title claims abstract description 121
- 201000010099 disease Diseases 0.000 title claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 10
- 230000009245 menopause Effects 0.000 title abstract 4
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 206010001497 Agitation Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000626 neurodegenerative effect Effects 0.000 claims description 3
- 206010029410 night sweats Diseases 0.000 claims description 3
- 230000036565 night sweats Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 231100000915 pathological change Toxicity 0.000 claims description 3
- 230000036285 pathological change Effects 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 25
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 12
- 238000011552 rat model Methods 0.000 description 11
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 10
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 10
- 229940028334 follicle stimulating hormone Drugs 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 206010060800 Hot flush Diseases 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000207925 Leonurus Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- -1 inorganic acid salt Chemical class 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 240000003271 Leonurus japonicus Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101810284A CN101732303B (zh) | 2008-11-21 | 2008-11-21 | 益母草碱用于更年期病症医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101810284A CN101732303B (zh) | 2008-11-21 | 2008-11-21 | 益母草碱用于更年期病症医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101732303A true CN101732303A (zh) | 2010-06-16 |
CN101732303B CN101732303B (zh) | 2012-02-01 |
Family
ID=42456673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101810284A Active CN101732303B (zh) | 2008-11-21 | 2008-11-21 | 益母草碱用于更年期病症医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101732303B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106619602A (zh) * | 2017-01-23 | 2017-05-10 | 南京医科大学 | 益母草碱的新用途 |
CN109692172A (zh) * | 2017-10-23 | 2019-04-30 | 珠海横琴新区中珠正泰医疗管理有限公司 | 益母草碱晶体及其在制备胰岛素增敏剂、降糖和降脂药物中的用途 |
CN113967206A (zh) * | 2021-09-01 | 2022-01-25 | 中国农业大学 | 益母草碱在治疗多囊卵巢综合征的药物中的应用 |
CN114452277A (zh) * | 2021-12-09 | 2022-05-10 | 澳门科技大学 | 益母草碱改善非酒精性脂肪肝和在肝脏脂质代谢中的用途 |
-
2008
- 2008-11-21 CN CN2008101810284A patent/CN101732303B/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106619602A (zh) * | 2017-01-23 | 2017-05-10 | 南京医科大学 | 益母草碱的新用途 |
CN106619602B (zh) * | 2017-01-23 | 2019-05-10 | 南京医科大学 | 益母草碱的用途 |
CN109692172A (zh) * | 2017-10-23 | 2019-04-30 | 珠海横琴新区中珠正泰医疗管理有限公司 | 益母草碱晶体及其在制备胰岛素增敏剂、降糖和降脂药物中的用途 |
WO2019080671A1 (zh) * | 2017-10-23 | 2019-05-02 | 珠海横琴新区中珠正泰医疗管理有限公司 | 益母草碱晶体及其在制备胰岛素增敏剂、降糖和降脂药物中的用途 |
US11446270B2 (en) | 2017-10-23 | 2022-09-20 | Zhuhai Hengqin New District Zhongzhu Zhengtai Medical Management Co., Ltd. | Leonurine crystal and use thereof in preparation of insulin sensitizer, hypoglycemic drug and lipid-lowering drug |
CN113967206A (zh) * | 2021-09-01 | 2022-01-25 | 中国农业大学 | 益母草碱在治疗多囊卵巢综合征的药物中的应用 |
CN114452277A (zh) * | 2021-12-09 | 2022-05-10 | 澳门科技大学 | 益母草碱改善非酒精性脂肪肝和在肝脏脂质代谢中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN101732303B (zh) | 2012-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McKenna et al. | Black cohosh: efficacy, safety, and use in clinical and preclinical applications | |
CN101732303B (zh) | 益母草碱用于更年期病症医药用途 | |
CN100394936C (zh) | 一种治疗崩漏的药物及其制备方法 | |
CN102218127B (zh) | 治疗痛经的中药组合物及其制备方法 | |
CN1475269A (zh) | 一种升麻精提物及其制备方法 | |
CN103142902B (zh) | 治疗乳腺增生疾病的中药组合物和制剂及其制备方法 | |
CN102579528B (zh) | 一种防治前列腺疾病的药物组合物 | |
CN103330919B (zh) | 一种治疗乳腺增生的中药复方霜剂及其制备方法 | |
CN101940585B (zh) | 一种以荭草素-2"-O-β-L-半乳糖苷为主要成分的组合物及其用途 | |
CN104645297A (zh) | 一种温宫助孕的中药组合物及其制剂制备方法 | |
CN101474189A (zh) | 卤米松药物制剂及制备方法 | |
CN110585365A (zh) | 一种具有治疗中枢性性早熟的复方组合物及其制备方法与应用 | |
CN1686272A (zh) | 治疗慢性前列腺炎的药物及其制备方法 | |
CN104189346A (zh) | 一种新型促胃肠动力的药物组合物及其制备方法 | |
CN111281911B (zh) | 一种药物组合物及其制备方法和治疗子宫内膜异位的用途 | |
CN103933152B (zh) | 治疗崩漏的药物组合物、药物制剂及应用和制法 | |
CN101693058B (zh) | 一种用于预防和治疗感冒及炎症感染的药物 | |
CN1301727C (zh) | 一种治疗皮肤病的外用中药制剂及其制备方法 | |
RU2710015C1 (ru) | Способ лечения генитоуринарного синдрома у женщин в менопаузе с помощью плацентарной терапии | |
CN102846760A (zh) | 一种桂枝茯苓汤整合型新剂型制备技术及其生产方法 | |
CN108339002B (zh) | 一种宠物用复方醋酸甲羟孕酮组合物及应用 | |
CN101361955B (zh) | 一种治疗类风湿疾病的中药组合物 | |
CN102579517B (zh) | 一种防治前列腺疾病的药物组合物 | |
CN103070857A (zh) | 丁苯酞的用途 | |
CN102908562B (zh) | 一种治疗乳腺疾病的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100616 Assignee: JINGDE XINXING BIOLOGY TECHNOLOGY Co.,Ltd. Assignor: Li Xiaoxiang Contract record no.: 2018340000012 Denomination of invention: Medicinal use of leonurine for menopause disease Granted publication date: 20120201 License type: Exclusive License Record date: 20180628 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Li Xiaoxiang Document name: payment instructions |